FDA Approves New Pancreatic Cancer Drug | US News

FDA just approved a groundbreaking new pill, Rasonque (daraxonrasib), for advanced pancreatic cancer patients who’ve exhausted other treatments. Targeting the RAS protein that fuels tumor growth, it boosted average survival to 13.2 months—up from 6.7 months with standard chemo. Easy to take once daily, it’s a major leap forward for a disease with few options. Pricing and availability remain unknown, but this approval offers hope and more time for those fighting one of medicine’s toughest cancers. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a6b216cc3bfdeda7